Task I: Single-dose Pharmacokinetic study - The contractor shall develop a single-dose, phase l clinical protocol for indole-3-carbinol to evaluate the parameters of drug absorption, plasma concentration-time profiles, distribution (in relevant tissues, where feasible), excretion, and toxicity. Protocol activation will occur following IRB and FDA approval and the receipt of all chemopreventive drug(s) from the NCI by the Contractor. The contractor shall submit the protocol to NCI DCPC Protocol Safety and Review Committee for review and comment, address all issues raised in the NCI review, and submit a finalized protocol for IRB approval. The contractor shall prepare all materials necessary for FDA approval. The NCI will submit the protocol to the FDA and will hold the IND. Task II: Multiple-dose Safety & Pharmacokinetic Study - The Contractor shall develop a multiple-dose safety and pharmacokinetic phase l clinical protocol for Indole-3-Carbinol to evaluate the parameters of safety and toxicity and of steady-state pharmacokinetics. In addition, investigations of pharmacological and/or cancer surrogate endpoint biomarker modulation may be undertaken (e.g. hormone levels (urinary 2- hydroxyestrone / estriol levels) and xenobiotic induction indicators].
| Reed, Gregory A; Arneson, Dora W; Putnam, William C et al. (2006) Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane. Cancer Epidemiol Biomarkers Prev 15:2477-81 |
| Reed, Gregory A; Peterson, Kirstin S; Smith, Holly J et al. (2005) A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 14:1953-60 |
